v3.26.1
Royalty Obligation (Details) - Royalty obligation - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Sep. 30, 2025
Mar. 31, 2026
Royalty Obligation    
Proceeds from royalty obligation $ 75,000 $ 75,000
Percentage of royalty on net sales 5.50%  
Percentage of royalty on net sales by licensees 5.50%  
Percentage of royalty on income earned from licensees 25.00%  
Percentage of royalty on non-royalty income earned from licensees 25.00%  
Additional payment $ 225,000  
Issuance costs 3,700 $ 3,691
Zenas' INDIGO Phase 3 Trial    
Royalty Obligation    
Additional payment 75,000  
FDA approval for IgG4-Related Disease    
Royalty Obligation    
Additional payment 75,000  
FDA for the treatment of systemic lupus erythematosus    
Royalty Obligation    
Additional payment $ 75,000